These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 36083516

  • 1. Brief Report: Intracellular Cystatin B Levels Are Altered in HIV-Infected Participants With Respect to Neurocognitive Status and Antiretroviral Therapy.
    Opsteen S, Moylan D, Taiwo BO, Robertson KR, Overton ET, Cutter GR, Sabbaj S, Heath SL, Shacka JJ.
    J Acquir Immune Defic Syndr; 2022 Dec 15; 91(5):485-489. PubMed ID: 36083516
    [Abstract] [Full Text] [Related]

  • 2. Circulating brain-derived extracellular vesicles expressing neuroinflammatory markers are associated with HIV-related neurocognitive impairment.
    de Menezes EGM, Liu JS, Bowler SA, Giron LB, D'Antoni ML, Shikuma CM, Abdel-Mohsen M, Ndhlovu LC, Norris PJ.
    Front Immunol; 2022 Dec 15; 13():1033712. PubMed ID: 36601110
    [Abstract] [Full Text] [Related]

  • 3. Plasma Cystatin C Associates With HIV-Associated Neurocognitive Disorder but Is a Poor Diagnostic Marker in Antiretroviral Therapy-Treated Individuals.
    Kalayjian RC, Robertson KR, Albert JM, Fichtenbaum CJ, Brown TT, Taiwo BO, ACTG 5303 Study Team.
    J Acquir Immune Defic Syndr; 2019 Jun 01; 81(2):e49-e54. PubMed ID: 30939531
    [Abstract] [Full Text] [Related]

  • 4. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
    Robertson KR, Jiang H, Kumwenda J, Supparatpinyo K, Marra CM, Berzins B, Hakim J, Sacktor N, Campbell TB, Schouten J, Mollan K, Tripathy S, Kumarasamy N, La Rosa A, Santos B, Silva MT, Kanyama C, Firhnhaber C, Murphy R, Hall C, Marcus C, Naini L, Masih R, Hosseinipour MC, Mngqibisa R, Badal-Faesen S, Yosief S, Vecchio A, Nair A, AIDS Clinical Trials Group.
    Clin Infect Dis; 2019 May 02; 68(10):1733-1738. PubMed ID: 30219843
    [Abstract] [Full Text] [Related]

  • 5. Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders.
    Cantres-Rosario Y, Plaud-Valentín M, Gerena Y, Skolasky RL, Wojna V, Meléndez LM.
    AIDS; 2013 Jan 28; 27(3):347-56. PubMed ID: 23291538
    [Abstract] [Full Text] [Related]

  • 6. Neurocognitive dysfunction in HIV-infected youth: investigating the relationship with immune activation.
    Eckard AR, Rosebush JC, O'Riordan MA, Graves CC, Alexander A, Grover AK, Lee ST, Habib JG, Ruff JH, Chahroudi A, McComsey GA.
    Antivir Ther; 2017 Jan 28; 22(8):669-680. PubMed ID: 28327462
    [Abstract] [Full Text] [Related]

  • 7. Declining Prevalence of Human Immunodeficiency Virus (HIV)-Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy-Treated Individuals With HIV.
    Mastrorosa I, Pinnetti C, Brita AC, Mondi A, Lorenzini P, Del Duca G, Vergori A, Mazzotta V, Gagliardini R, Camici M, De Zottis F, Fusto M, Plazzi MM, Grilli E, Bellagamba R, Cicalini S, Antinori A.
    Clin Infect Dis; 2023 Feb 08; 76(3):e629-e637. PubMed ID: 35982541
    [Abstract] [Full Text] [Related]

  • 8. Lifetime antiretroviral exposure and neurocognitive impairment in HIV.
    Amusan P, Power C, Gill MJ, Gomez D, Johnson E, Rubin LH, Fujiwara E.
    J Neurovirol; 2020 Oct 08; 26(5):743-753. PubMed ID: 32720232
    [Abstract] [Full Text] [Related]

  • 9. Markers of extracellular matrix degradation and inflammasome activation are associated with carotid plaques in virally suppressed people with HIV in Botswana.
    Ueland T, Nkele I, Hoel H, Lockman S, Michelsen AE, Moshomo T, Aukrust P, Mohammed T, Trøseid M, Mosepele M.
    AIDS; 2025 Jan 01; 39(1):22-30. PubMed ID: 39283741
    [Abstract] [Full Text] [Related]

  • 10. Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.
    Coban H, Robertson K, Smurzynski M, Krishnan S, Wu K, Bosch RJ, Collier AC, Ellis RJ.
    AIDS; 2017 Jul 17; 31(11):1565-1571. PubMed ID: 28471765
    [Abstract] [Full Text] [Related]

  • 11. Absence of neurocognitive disadvantage associated with paediatric HIV subtype A infection in children on antiretroviral therapy.
    Bangirana P, Ruel TD, Boivin MJ, Pillai SK, Giron LB, Sikorskii A, Banik A, Achan J.
    J Int AIDS Soc; 2017 Oct 17; 20(2):. PubMed ID: 29052340
    [Abstract] [Full Text] [Related]

  • 12. Circulating plasma-derived extracellular vesicles expressing bone and kidney markers are associated with neurocognitive impairment in people living with HIV.
    Marques de Menezes EG, Bowler SA, Shikuma CM, Ndhlovu LC, Norris PJ.
    Front Neurol; 2024 Oct 17; 15():1383227. PubMed ID: 38725641
    [Abstract] [Full Text] [Related]

  • 13. [Neurocognitive impairment and characteristics of neurocognitive performance among people with HIV on antiretroviral treatment].
    Xia JJ, Wang SL, Hu YF, Shen WW, Lin HJ, Shi RZ, Ma ZH, Li ZH, Li SZ, Ding YY, Chen XX, He N.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Oct 10; 43(10):1651-1657. PubMed ID: 36456499
    [Abstract] [Full Text] [Related]

  • 14. Antiretroviral treatment initiation does not differentially alter neurocognitive functioning over time in youth with behaviorally acquired HIV.
    Nichols SL, Bethel J, Kapogiannis BG, Li T, Woods SP, Patton ED, Ren W, Thornton SE, Major-Wilson HO, Puga AM, Sleasman JW, Rudy BJ, Wilson CM, Garvie PA, Adolescent Medicine Trials Network for HIV/AIDS Interventions.
    J Neurovirol; 2016 Apr 10; 22(2):218-30. PubMed ID: 26463526
    [Abstract] [Full Text] [Related]

  • 15. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda.
    Rubin LH, Saylor D, Nakigozi G, Nakasujja N, Robertson K, Kisakye A, Batte J, Mayanja R, Anok A, Lofgren SM, Boulware DR, Dastgheyb R, Reynolds SJ, Quinn TC, Gray RH, Wawer MJ, Sacktor N.
    J Neurovirol; 2019 Dec 10; 25(6):800-813. PubMed ID: 31218522
    [Abstract] [Full Text] [Related]

  • 16. Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy.
    Fields JA, Swinton MK, Soontornniyomkij B, Carson A, Achim CL.
    AIDS; 2020 Jun 01; 34(7):1001-1007. PubMed ID: 32073451
    [Abstract] [Full Text] [Related]

  • 17. Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy: analysis from a randomized placebo-controlled trial.
    Decloedt EH, Lesosky M, Maartens G, Joska JA.
    AIDS Res Ther; 2017 Feb 04; 14(1):6. PubMed ID: 28160772
    [Abstract] [Full Text] [Related]

  • 18. Macrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesis.
    Rivera LE, Colon K, Cantres-Rosario YM, Zenon FM, Melendez LM.
    Curr HIV Res; 2014 Feb 04; 12(2):111-20. PubMed ID: 24862331
    [Abstract] [Full Text] [Related]

  • 19. HIV-associated neurocognitive disorder is associated with HIV-1 dual infection.
    Wagner GA, Chaillon A, Liu S, Franklin DR, Caballero G, Kosakovsky Pond SL, Vaida F, Heaton RK, Letendre SL, Grant I, Richman DD, Smith DM.
    AIDS; 2016 Nov 13; 30(17):2591-2597. PubMed ID: 27536983
    [Abstract] [Full Text] [Related]

  • 20. Mechanisms of CNS Viral Seeding by HIV+ CD14+ CD16+ Monocytes: Establishment and Reseeding of Viral Reservoirs Contributing to HIV-Associated Neurocognitive Disorders.
    Veenstra M, León-Rivera R, Li M, Gama L, Clements JE, Berman JW.
    mBio; 2017 Oct 24; 8(5):. PubMed ID: 29066542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.